No abstract

IntroductionThe distribution of the demand from primary care in the mental health units could be a way of facilitating the coordination and improving the attention to patients. For this reason, in our unit we have made a repartition of the areas among the different psychiatrists.ObjectivesTo analyze if there was a correlation between the geographical origin of the patients or their primary care areas and the referrals, and between them and their attendance.MethodsThis is an epidemiological, analytic, prospective study of patients referred to our department. The following variables were collected: (1) referral protocol, (2) reason, (3) demographic data (origin, gender, age), (4) Primary Care area, (5) attendance to appointment, (6) diagnosis impression and (7) destination of referral. The SPSS 19.0 was used to analyze the data.ResultsA total of 1048 patients were sampled. A statistically significant relationship hasn’t been found between place of residence, primary care area or areas of distribution in the Unit and attendance (Chi2). If we analyze the population of each distribution, we can describe similar percentages depending on the size of these.ConclusionsAlthough a different distribution and a relationship is thought between some areas and the attendance or the number of referrals, we didn’t find out them in our sample.Disclosure of interestThe authors have not supplied their declaration of competing interest.

Introduction Binge-eating disorder (BED), is one of the most common eating disorder. Treatment aims to reduce binge-eating frequency and disordered eating–related cognitions, improve metabolic health and weight, and regulate mood (in patients with coexisting depression or anxiety) Objectives The aim of this study was to examine the efficacy of lisdexamfetamine dimesylate in a simple of 50 women with a binge eating disorder diagnosis compare with selective serotonin reuptake inhibitor Methods Two groups were made, one with lisdexamfetamine and the other with selective serotonin reuptake inhibitor (fluoxetine). 20 women were in each group (total n=40). The doses depend of the binge symptoms and rates were from 30 to 70md/day for lisdexamfetamine and for fluoxetine the doses were from 20 to 60mg/day. Results Binge behaviors decreased with a 50mg/day dose of lisdexamfetamine. The 70mg/day doses present also less binge behaviors but also more adverse events. The 30mg/day doses did not decrease binge-eating behaviors. Conclusions Lisdexamfetamine is the first pharmacological agent to receive FDA approval for use in adults with moderate to severe binge eating disorder. This study supports further assessment of lisdexamfetamine as a treatment option for decreasing binge eating behavior and also symptoms associated such as anxiety and obsessive and compulsive features in adults.Increased efficacy with increasing dosages of lisdexamfetamine suggests a dose-response relationship until 50mg/day. Women with a dose of 50mg/day of lisdexamfetamine report less adverse event, more adherence to treatment and improve their eating behaviors. Disclosure No significant relationships.

Introduction Antisocial disorder is characterised by difficulty to adapt to social norms that normally rule different aspects of the person’s conduct in adolescence and adulthood. According to DSM-V, this disorder’s prevalence stands between 0.2% and 3%, and is more frequent in men. Objectives Numerous studies have been made about the influence between the environment and genetics for the development of this disorder, finding in several patients a punctual mutation of the monoamine oxidase gen (MAOA); although impulsive behaviour has also been associated to the 5-HT tranporte gene (5-HTT), and the protein coding gene for Tryptophan Hydroxylase TPH1 Methods The hospital admission for these patients must be made when there’s autoregressive or hetero aggressive behaviour, suicide attempts, psychotic symptoms, or symptoms that generate important repercussions in the person’s normal functions. Nevertheless, is important to identify during the hospitalization the improvement possibilities of these patients in order to make drug or psychotherapy adjustments; in the case that we don’t observe treatment benefits, the patient will be released from the hospitalization Results The main treatment is psychotherapy. Conclusions There’s not much evidence of drug use in this disorder, however, mood stabilizers, antidepressants, atypical antipshychotics and benzodiazepines are used for rage control, impulsiveness, anxiety and aggressiveness. Disclosure No significant relationships.

La superposición entre los trastornos del espectro autista (TEA) y los trastornos de la conducta alimentaria (TCA) lleva tiempo estudiándose, encontrándose sobre todo similitudes en ciertas características cognitivas. El objetivo de este trabajo es analizar la bibliografía disponible acerca de la relación entre los síntomas que corresponden al espectro autista con las diferentes patologías que se engloban dentro de los TCA. La información fue recogida a partir de diferentes bases de datos (Pubmed, Cochrane, Tripdatabase, UpToDate) entre 2013 y 2018. Se emplean los descriptores “eating disorders”, “autism”, “treatment”, “psychotherapy”, “anorexia nervosa”, “bulimia nervosa”, “food avoidant/restriction intake disorder” “binge eating disorder” “obesity” y “adolescence”; así como sus equivalentes en español. Los estudios publicados, referidos a lo largo del texto, sobre todo se refieren a la anorexia nerviosa (AN), existiendo menos investigaciones realizadas con otras patologías alimentarias como obesidad, bulimia, y trastorno por atracón. Sin embargo, y a pesar que sobre todo se señale la relación con la AN, existen características a nivel cognitivo que son compartidas entre los TCA y los TEA que han de ser tenidas en cuenta por sus implicaciones tanto en el tratamiento como en el pronóstico.